Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Hypoxia D000860 23 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Tumor Virus Infections D014412 8 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Pain D010146 64 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Pulmonary Fibrosis D011658 24 associated lipids
Wounds and Injuries D014947 20 associated lipids
Pleurisy D010998 20 associated lipids
Burns D002056 34 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Inflammation D007249 119 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Infertility, Male D007248 11 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Brain Injuries D001930 4 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Gastritis D005756 27 associated lipids
Pulmonary Edema D011654 23 associated lipids
Coronary Disease D003327 70 associated lipids
Intestinal Obstruction D007415 6 associated lipids
Pancreatitis D010195 10 associated lipids
Liver Cirrhosis, Experimental D008106 36 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Rhinitis D012220 10 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Asphyxia Neonatorum D001238 4 associated lipids
Melanoma D008545 69 associated lipids
Asthma D001249 52 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Staphylococcal Infections D013203 15 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Metabolism, Inborn Errors D008661 46 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Thrombosis D013927 49 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Peritonitis D010538 38 associated lipids
Hemorrhage D006470 15 associated lipids
Proteinuria D011507 30 associated lipids
Spasm D013035 5 associated lipids
Lymphoma D008223 18 associated lipids
Alzheimer Disease D000544 76 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Arteriosclerosis D001161 86 associated lipids
Leukemia D007938 74 associated lipids
Neuroblastoma D009447 66 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Thalassemia D013789 8 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Cholestasis D002779 23 associated lipids
Fibrosis D005355 23 associated lipids
Anemia, Sickle Cell D000755 34 associated lipids
Multiple Sclerosis D009103 13 associated lipids
Glomerulonephritis D005921 35 associated lipids
Nervous System Diseases D009422 37 associated lipids
Psoriasis D011565 47 associated lipids
Brain Edema D001929 20 associated lipids
Leukopenia D007970 9 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Staphylococcal Skin Infections D013207 9 associated lipids
Burns, Inhalation D002059 4 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Fetal Weight D020567 12 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Stroke D020521 32 associated lipids
Hyperlipoproteinemia Type II D006938 22 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemia D007511 18 associated lipids
Colonic Diseases D003108 5 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Hwang SB et al. Specific receptor sites for 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes. 1983 Biochemistry pmid:6313047
Wasserman SI Mediators of immediate hypersensitivity. 1983 J. Allergy Clin. Immunol. pmid:6193157
MacIntyre DE and Pollock WK Platelet-activating factor stimulates phosphatidylinositol turnover in human platelets. 1983 Biochem. J. pmid:6411067
Hopkins NK et al. Evidence for mediation of acetyl glyceryl ether phosphorylcholine stimulation of adenosine 3',5'-(cyclic)monophosphate levels in human polymorphonuclear leukocytes by leukotriene B4. 1983 Biochim. Biophys. Acta pmid:6313071
Mencia-Huerta JM et al. Antigen-initiated release of platelet-activating factor (PAF-acether) from mouse bone marrow-derived mast cells sensitized with monoclonal IgE. 1983 J. Immunol. pmid:6315819
Czarnetzki B Increased monocyte chemotaxis towards leukotriene B4 and platelet activating factor in patients with inflammatory dermatoses. 1983 Clin. Exp. Immunol. pmid:6317241
Stimler NP and O'Flaherty JT Spasmogenic properties of platelet-activating factor: evidence for a direct mechanism in the contractile response of pulmonary tissues. 1983 Am. J. Pathol. pmid:6624879
Hartung HP Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. Studies on PGE, TXB2 and O2- production, spreading, and the influence of calmodulin-inhibitor W-7. 1983 FEBS Lett. pmid:6309563
Swendsen CL et al. 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine: a novel source of arachidonic acid in neutrophils stimulated by the calcium ionophore A23187. 1983 Biochem. Biophys. Res. Commun. pmid:6407484
Shukla SD et al. Acetylglyceryl ether phosphorylcholine. A potent activator of hepatic phosphoinositide metabolism and glycogenolysis. 1983 J. Biol. Chem. pmid:6309795
Hallam TJ et al. The role of 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (AcGEPC) and palmitoyl-lysophosphatidate in the responses of human blood platelets to collagen and thrombin. 1983 FEBS Lett. pmid:6617886
Roussi J et al. [Success of treatment with a low-molecular-weight heparin fraction in a case of pulmonary embolism complicated by heparin-induced thrombopenia]. 1983 Nouv Rev Fr Hematol pmid:6622253
Valone FH and Goetzl EJ Enhancement of human polymorphonuclear leukocyte adherence by the phospholipid mediator 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine (AGEPC). 1983 Am. J. Pathol. pmid:6624880
Barradas MA et al. The effect of fenfluramine on collagen-induced platelet aggregation in vitro. 1983 Br J Clin Pharmacol pmid:6626443
Heffner JE et al. Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2. 1983 J. Clin. Invest. pmid:6822668
Keraly CL et al. Effect of structural analogues of PAF-acether on platelet desensitization. 1983 Br. J. Haematol. pmid:6824590
Tence M et al. The enantiomer and the positional isomer of platelet-activating factor. 1983 Biochim. Biophys. Acta pmid:6824744
Camussi G et al. Biosynthesis and release of platelet-activating factor from human monocytes. 1983 Int. Arch. Allergy Appl. Immunol. pmid:6826235
Randolph AE et al. Blood pressure and heart rate effects of alkyl ether phospholipids in conscious renal, spontaneously hypertensive, and normotensive rats. 1983 Clin Exp Hypertens A pmid:6684006
Morley J et al. Inflammatory actions of platelet activating factor (Pafacether) in guinea-pig skin. 1983 Br. J. Pharmacol. pmid:6685552
Hornby EJ and Perry CR 1-O-hexadecyl-2-acetyl-sn-3-glycerophosphorylcholine (PAF): some effects on the aggregation of human platelets by thrombin or collagen. 1983 Thromb. Haemost. pmid:6636035
Patterson R and Harris KE The activity of aerosolized and intracutaneous synthetic platelet activating factor (AGEPC) in rhesus monkeys with IgE-mediated airway responses and normal monkeys. 1983 J. Lab. Clin. Med. pmid:6644157
Nunn B Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. 1983 Thromb. Res. pmid:6648898
Myers A et al. Glucocorticoid protection against PAF-acether toxicity in mice. 1983 Br. J. Pharmacol. pmid:6652344
Cervoni P et al. Aortic vascular and atrial responses to (+/-)-1-O-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine. 1983 Br. J. Pharmacol. pmid:6652348
Ogihara T et al. [Renomedullary hypotensive lipids and prostaglandins]. 1983 Horumon To Rinsho pmid:6368051
Benveniste J et al. The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations. 1983 Br. J. Pharmacol. pmid:6652376
Garcia Gil M and Sanchez Crespo M Dansylcadaverine and rimantadine inhibition of phagocytosis, PAF-acether release, and phosphatidylcholine synthesis in human polymorphonuclear leukocytes. 1983 Immunopharmacology pmid:6654649
Tokumura A et al. Biphasic action of platelet-activating factor on isolated guinea-pig ileum. 1983 Lipids pmid:6656539
Hamasaki Y et al. [Effects of platelet activating factor (PAF:AGEPC) on airway and pulmonary vascular constriction of guinea pigs--with special reference to the relation with TXA2]. 1983 Kokyu To Junkan pmid:6658209
Mueller HW et al. Biosynthesis of platelet activating factor in rabbit polymorphonuclear neutrophils. 1983 J. Biol. Chem. pmid:6406476
Billah MM and Johnston JM Identification of phospholipid platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in human amniotic fluid and urine. 1983 Biochem. Biophys. Res. Commun. pmid:6407483
Worthen GS et al. Platelet-activating factor causes neutrophil accumulation and edema in rabbit lungs. 1983 Chest pmid:6839840
Heffner JE et al. Platelet-induced pulmonary hypertension and edema. A mechanism involving acetyl glyceryl ether phosphorylcholine and thromboxane A2. 1983 Chest pmid:6839854
Levy JV Calmodulin antagonist W-7 inhibits aggregation of human platelets induced by platelet activating factor. 1983 Proc. Soc. Exp. Biol. Med. pmid:6844347
O'Flaherty JT et al. Platelet-activating factor and analogues: comparative studies with human neutrophils and rabbit platelets. 1983 Res. Commun. Chem. Pathol. Pharmacol. pmid:6844746
Valone FH and Goetzl EJ Specific binding by human polymorphonuclear leucocytes of the immunological mediator 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine. 1983 Immunology pmid:6848449
Chilton FH et al. Metabolic fate of platelet-activating factor in neutrophils. 1983 J. Biol. Chem. pmid:6853486
Stormorken H et al. A new bleeding disorder: lack of platelet aggregatory response to adrenaline and lack of secondary aggregation to ADP and platelet activating factor (PAF). 1983 Thromb. Res. pmid:6857589
Kloprogge E et al. Stimulus-response coupling in human platelets. Evidence against a role of PAF-acether in the "third pathway'. 1983 Thromb. Res. pmid:6857605
Chilton FH et al. Selective acylation of lyso platelet activating factor by arachidonate in human neutrophils. 1983 J. Biol. Chem. pmid:6408071
Lecrubier C et al. Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. 1983 Agents Actions pmid:6858789
Gonzalez-Crussi F and Hsueh W Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin. 1983 Am. J. Pathol. pmid:6859226
Camussi G et al. Acute lung inflammation induced in the rabbit by local instillation of 1-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine or of native platelet-activating factor. 1983 Am. J. Pathol. pmid:6859232
Cargill DI et al. Aggregation, release and desensitization induced in platelets from five species by platelet activating factor (PAF). 1983 Thromb. Haemost. pmid:6879508
Sánchez-Crespo M et al. Presence in normal human urine of a hypotensive and platelet-activating phospholipid. 1983 Am. J. Physiol. pmid:6859262
Lumb RH et al. Spontaneous and protein-catalyzed transfer of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) between phospholipid bilayers. 1983 Biochim. Biophys. Acta pmid:6860678
Suquet CM and Leid RW Aggregation of equine platelets by PAF (platelet-activating factor). 1983 Inflammation pmid:6862593
Virella G et al. Release of PAF by human polymorphonuclear leucocytes stimulated by immune complexes bound to Sepharose particles and human erythrocytes. 1983 Immunology pmid:6885111
Camussi G et al. Platelet-activating factor-mediated contraction of rabbit lung strips: pharmacologic modulation. 1983 Immunopharmacology pmid:6885382
Hubbard JW et al. Antihypertensive effects of I-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine on plasma renin activity and catecholamine responses in spontaneously hypertensive rats. 1983 Life Sci. pmid:6337313
Acharya SB and MacIntyre DE Platelet products and vascular PGI2 production. 1983 Prostaglandins Leukot Med pmid:6338532
Camussi G et al. Effect of prostacyclin (PGI2) on immune-complex-induced neutropenia. 1983 Immunology pmid:6339375
Billah MM and Lapetina EG Platelet-activating factor stimulates metabolism of phosphoinositides in horse platelets: possible relationship to Ca2+ mobilization during stimulation. 1983 Proc. Natl. Acad. Sci. U.S.A. pmid:6341992
Lapetina EG and Siegel FL Shape change induced in human platelets by platelet-activating factor. Correlation with the formation of phosphatidic acid and phosphorylation of a 40,000-dalton protein. 1983 J. Biol. Chem. pmid:6345519
Camussi G et al. Inhibitory effect of prostacyclin (PGI2) on neutropenia induced by intravenous injection of platelet-activating-factor (PAF) in the rabbit. 1983 Prostaglandins pmid:6346397
Iñarrea P et al. Platelet-activating factor: an effector substance of the vasopermeability changes induced by the infusion of immune aggregates in the mouse. 1983 Immunopharmacology pmid:6347969
Satouchi K [Platelet activating factor (PAF)--a new chemical mediator of inflammation]. 1983 Seikagaku pmid:6350499
Lin AH et al. Acetyl glyceryl ether phosphorylcholine stimulates leukotriene B4 synthesis in human polymorphonuclear leukocytes. 1982 J. Clin. Invest. pmid:6290535
Vargaftig BB et al. Adrenaline and PAF-acether synergize to trigger cyclooxygenase-independent activation of plasma-free human platelets. 1982 Thromb. Res. pmid:7164036
Mencia-Huerta JM et al. Biosynthesis of platelet-activating factor (PAF)acether). III. Formation of PAF-acether from synthetic substrates by stimulated murine macrophages. 1982 J. Immunol. pmid:7086143
Wykle RL et al. Platelet activating factor (1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine). Activity of analogs lacking oxygen at the 2-position. 1982 FEBS Lett. pmid:7084476
Sánchez-Crespo M et al. Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: evidence for a platelet independent mechanism. 1982 Immunopharmacology pmid:7085259
Bach MK Mediators of anaphylaxis and inflammation. 1982 Annu. Rev. Microbiol. pmid:6128957
Mueller HW et al. Ether lipid content and fatty acid distribution in rabbit polymorphonuclear neutrophil phospholipids. 1982 Lipids pmid:7087685
Page CP et al. Platelet activation in asthma. 1982 N. Engl. J. Med. pmid:7088080
Chilton FH et al. Platelet activating factor. Stimulation of the lipoxygenase pathway in polymorphonuclear leukocytes by 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine. 1982 J. Biol. Chem. pmid:6802816
Vargaftig BB et al. Degranulation of rabbit platelets with PAF-acether: a new procedure for unravelling the mode of action of platelet-activating substances. 1982 Thromb. Haemost. pmid:7135345
Sancho J et al. The effect of the injection of a synthetic platelet-activating factor (PAF-acether) on the fate of IgG aggregates in mice. 1982 Immunology pmid:7141463
Sybertz EJ et al. Studies on the interactions of acetyl glycerol ether phosphoryl choline with the sympathetic nervous system in rats. 1982 J. Pharmacol. Exp. Ther. pmid:7143227
Cabot MC et al. Metabolism of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by cell cultures. 1982 Life Sci. pmid:7162357
Tsien WH et al. Variable responses of human platelets to synthetic platelet activating factor and their modification by epinephrine. 1982 Thromb. Res. pmid:7164038
Vargaftig BB Platelet-activating factor (PAF-acether) 1982 Agents Actions pmid:7164939
Bette P and Bienvenue A Exchange of a spin-labeled analog of PAF-acether between micelles, serum albumin and model membranes. 1982 Agents Actions pmid:7164940
Roubin R et al. Release of platelet-activating factor (PAF-acether) and leukotrienes C and D from inflammatory macrophages. 1982 Eur. J. Immunol. pmid:6122581
O'Flaherty JT Lipid mediators of inflammation and allergy. 1982 Lab. Invest. pmid:6126615
Pinckard RN The "new" chemical mediators of inflammation. 1982 Monogr Pathol pmid:6126808
Robeva R et al. [Changes in blood coagulation in glomerulonephritis]. 1982 Vutr Boles pmid:6219496
Chignard M et al. Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea pig. 1982 Eur. J. Pharmacol. pmid:6804248
Shukla SD and Hanahan DJ AGEPC (platelet activating factor) induced stimulation of rabbit platelets: effects on phosphatidylinositol, di- and triphosphoinositides and phosphatidic acid metabolism. 1982 Biochem. Biophys. Res. Commun. pmid:6288030
Alonso F et al. Modulatory role of cyclic AMP in the release of platelet-activating factor from human polymorphonuclear leucocytes. 1982 Immunology pmid:6277775
Rao GH et al. Human platelet activation by an alkylacetyl analogue of phosphatidylcholine. 1982 Biochim. Biophys. Acta pmid:6280777
Ingraham LM et al. Metabolic, membrane, and functional responses of human polymorphonuclear leukocytes to platelet-activating factor. 1982 Blood pmid:6282362
Valone FH et al. Specific binding of phospholipid platelet-activating factor by human platelets. 1982 J. Immunol. pmid:6286773
Lüscher EF The role of blood cells and of the vessel wall in the induction of intravascular coagulation. 1982 Klin. Wochenschr. pmid:6750223
Yasaka T et al. Monocyte aggregation and superoxide anion release in response to formyl-methionyl-leucyl-phenylalanine (FMLP) and platelet-activating factor (PAF). 1982 J. Immunol. pmid:6278021
Morgan WK et al. Byssinosis: some unanswered questions. 1982 Am. Rev. Respir. Dis. pmid:6808880
Myśliwiec M and Myśliwiec B [Blood platelets, prostaglandin and complement interactions in inflammation]. 1982 Prz. Lek. pmid:6753039
Miller OV et al. Acetyl glycerylphosphorylcholine inhibition of prostaglandin I2-stimulated adenosine 3',5'-cyclic monophosphate levels in human platelets. Evidence for thromboxane A2 dependence. 1982 Biochim. Biophys. Acta pmid:6285985
Miller CL Infection in massively injured patients. 1982 Prog. Clin. Biol. Res. pmid:6757964
Bruni A and Palatini P Biological and pharmacological properties of phospholipids. 1982 Prog Med Chem pmid:6758038
Masugi F et al. [Platelet-activating factor and antihypertensive polar renomedullary lipid: 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine]. 1982 Tanpakushitsu Kakusan Koso pmid:6758041
Modiano A and Belisario A [Recent information on PAF (Platelet Activating Factor) in hemocoagulative and immuno-allergic processes]. 1982 G Clin Med pmid:6762313
Marcus AJ et al. Arachidonic acid metabolism in endothelial cells and platelets. 1982 Ann. N. Y. Acad. Sci. pmid:6762834
Jouvin-Marche E et al. Platelet-activating factor (PAF-acether), an activator of neutrophil functions. 1982 Agents Actions pmid:6299078
Caillard CG et al. Hypotensive activity of PAF-acether in rats. 1982 Agents Actions pmid:6299079
Hartung HP et al. Stimulation of the oxidative burst in macrophages with platelet activating factor (PAF-acether). 1982 Agents Actions Suppl. pmid:6960648
Camussi G et al. Release of platelet-activating factor from HL-60 human leukemic cells following macrophage-like differentiation. 1982 Blood pmid:6947829
Ishii H et al. A platelet aggregating substance contained in xanthine oxidase preparation from cow's milk. 1982 Thromb. Res. pmid:6897588
Smith RJ and Bowman BJ Stimulation of human neutrophil degranulation with 1-O-octadecyl-2-O-acetyl-SN-glyceryl-3-phosphorylcholine: modulation by inhibitors of arachidonic acid metabolism. 1982 Biochem. Biophys. Res. Commun. pmid:6803804